LEGN - Legend Biotech Corporation - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

10.71B

Cash

850.1M

Avg Qtr Burn

-65.91M

Short % of Float

0.00%

Insider Ownership

1.42%

Institutional Own.

39.27%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details Blood cancer, Cancer, Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CARVYKTI (cilta-cel) [sNDA] Details Blood cancer, Cancer, Multiple myeloma	sNDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB1908 (targeting Claudin 18.2) Details Cancer, Esophageal cancer, Pancreatic cancer, Gastric cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB1901 (antiCD4) Details Cancer, T-cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.